Background/Aims: The translocation of bacteria and their lipopolysaccharides from the gut can promote fibrosis in cirrhotic patients. The aim of this study was to investigate the effects of rifaximin on hepatic fibrosis in a bile duct-ligated rat model. Methods: The bile duct ligation (BDL) was carried out for eight days (acute injury model: sham-operated rats [G1], BDL rats [G2], and BDL rats treated with rifaximin [G3]) or 22 days (chronic injury model: sham-operated rats [G4], BDL rats [G5], and BDL rats treated with rifaximin [G6]). Rifaximin (50 mg/kg/day) was administered daily via gavage after BDL. Liver function, serum tumor necrosis factor-alpha (TNF-α), and hepatic hydroxyproline levels were measured. Moreover, a histological analysis of fibrosis contents was performed using sirius red stain. Results: In the acute injury model, the liver function and TNF-α level were not improved after the rifaximin treatment. The hydroxyproline levels (μg/g liver tissue) in G1, G2, and G3 were 236.4±103.1, 444.8±114.4, and 312.5±131.6, respectively; and fibrosis contents (%) were 0.22±0.04, 1.64±0.53, and 1.66±0.44, respectively. The rifaximin treatment did not ameliorate acute BDL-induced fibrosis. In the chronic injury model, the hydroxyproline levels in G4, G5, and G6 were 311.5±72.9, 1,110.3±357.9, and 944.3±209.3, respectively; and fibrosis contents (%) were 0.19±0.03, 5.04±0.18, and 4.42±0.68, respectively (G5 vs. G6, p=0.059). The rifaximin treatment marginally ameliorated chronic BDL-induced fibrosis. Conclusions: Rifaximin did not reduce inflammation and fibrosis in bile duct-ligated rat model. (Korean J Gastroenterol 2017;70:239-246) 
INTRODUCTION
Liver fibrosis and cirrhosis, the end-stage of hepatic fibrosis are the major causes of morbidity and mortality in patients with chronic liver disease. 1 Activation of hepatic stellate cells (HSCs) in response to liver injury and the initiation of unbalanced synthesis of collagen are the main steps in the pathogenesis of fibrosis. 2 Cirrhosis is characterized by architectural distortion of the liver, including diffuse parenchymal nodularity, fibrosis, and vascular changes in variable severity. and hepatic stellate cells, also respond to bacterial products through TLRs. [4] [5] [6] [7] Rifaximin is a non-absorbable antibiotic used for intestinal decontamination. It can be an effective treatment for subclinical and overt hepatic encephalopathy. It was reported to reduce endotoxemia and severity of liver disease in humans. 8 In a recent animal study, rifaximin was reported to inhibit TLR4 dependent fibronectin mediated crosstalk, between stellate cells and endothelial cells in liver fibrosis in a 21-day bile duct-ligated mice model. 9 However, inflammation and fibrosis were not simultaneously investigated. Those were not explored in the early stages of hepatic fibrosis on rifaximin treatment.
Therefore, in this study, we investigated the effects of rifaximin on hepatic inflammation and fibrosis in a bile duct-ligated rat model of acute and chronic liver injury.
SUBJECTS AND METHODS

Materials and animal experiments
Rifaximin was provided by Hanall Biopharma (Seoul, Korea Fig. 1 ).
Bile duct ligation
For all surgical procedures, the rats were anesthetized by inhalation of 5 vol% isoflurane in 100% oxygen at a flow rate of 4 L/min for the induction and 2-3 vol% at 2 L/min for the maintenance. In the sham operated group, a midline incision in the abdomen was made using the sterile techniques. In the BDL and BDL-rifaximin groups, after a midline laparotomy of 1-2 cm, the common bile duct was identified, doubly ligated dissected liver samples were fixed, processed, and paraffin-embedded for histologic examination. Liver tissues were snap-frozen in liquid nitrogen and stored at -80℃ for further analysis. All animal experiments were approved by the Gachon University Institutional Animal Care and Use Committee (LCDI-2015-0009).
Serum biochemistry
Serum total bilirubin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels were analyzed with an automatic analyzer (cobas c111 system; Roche Diagnostics Ltd., Rotkreuz, Switzerland).
Determination of serum tumor necrosis factor-alpha (TNF-α) level
Serum TNF-α levels were measured using the commercial enzyme linked immunosorbent assay kit (R&D systems, Minneapolis, MN, USA) according to the manufacturer's instructions. The absorbance was recorded using an EMax ® microplate reader (Molecular Devices, Sunnyvale, CA, USA), and concentrations were calculated based on the standard curve.
Hepatic hydroxyproline content
Hepatic hydroxyproline levels were quantified in accordance with the manufacturer's protocol using the colorimetric hydroxyproline assay kit (Biovision, Mountview, CA, USA).
Liver tissue (10 mg was measured. The data were pooled to determine the mean.
Statistical analysis
The data are presented as the mean±standard deviation.
Statistical significance of the difference between the experimental groups was assessed using two-tailed Student's t-test. A p-value of less than 0.05 was considered statistically significant.
RESULTS
Effect of rifaximin on serum biochemistry in acute or chronic injury model
The total bilirubin levels were higher in BDL (BDL G2 and G5) and BDL-rifaximin groups (BDL-rifaximin G3 and G6) than in the sham groups (sham G1 and G4). However, the total bilirubin levels were not different between the BDL and BDL-rifaximin groups. Similarly, the serum AST and ALT levels were also higher in the BDL (BDL G2 and G5) and BDL-rifaximin groups (BDL-rifaximin G3 and G6) than in the sham groups (sham G1 and G4). However, the serum AST levels were not different between the BDL and BDL-rifaximin groups. In the case of serum ALT levels, there was no difference between BDL G2 and BDL-rifaximin G3. Moreover, the serum ALT level was rather higher in BDL-rifaximin G6 than in BDL G5 (Fig. 2 ). 
Effect
Effect of rifaximin on hydroxyproline level in acute or chronic injury model
The hydroxyproline levels (μg/g liver tissue) in sham G1, BDL G2, and BDL-rifaximin G3 were 236.4±103.1, 444.8± 114.4, and 312.5±131.6, respectively. The level was significantly higher in BDL G2 than in sham G1 (p=0.010).
Although the level was lower in BDL-rifaximin G3 than in BDL G2, rifaximin treatment did not lead to a statistically significant reduction in the hydroxyproline level (Fig. 4A) . The hydroxyproline levels in sham G4, BDL G5, and BDL-rifaximin G6 were 311.5±72.9, 1,110.3±357.9, and 944.3±209.3, respectively.
The level was significantly higher in BDL G5 than in sham G4 (p<0.001). Although the level was lower in BDL-rifaximin G6 than in BDL G5, rifaximin treatment did not lead to statistically significant reduction in the level of hydroxyproline (Fig. 4B ).
Effect of rifaximin on fibrosis content in acute or chronic injury model
H&E staining of the liver from chronic injury model showed an increased inflammatory cell infiltration with bridging necrosis and fibrotic band interposition. H&E staining did not reveal any histological improvement after the rifaximin treatment ( Fig. 5 ). After sirius red staining, remarkable collagen accumulation was observed in the BDL groups, based on the hyperplasia of the lattice fibers and collagenous fibers in the portal area. In both acute and chronic injury models, collagen accumulation measured by sirius red staining in the BDL-rifaximin groups was not different from that in the BDL groups (Fig. 6A, B) content was significantly higher in BDL G2 than in sham G1 (p=0.001), there was no difference between BDL G2 and BDL-rifaximin G3 (Fig. 6C ). In the chronic injury model, the collagen contents (%) in sham G4, BDL G5, and BDL-rifaximin G6 were 0.19±0.03, 5.04±0.18, and 4.42±0.68, respectively.
While the fibrosis content was significantly higher in BDL G5 than in sham G4 (p<0.001), it was marginally decreased by the rifaximin treatment in BDL-rifaximin G6 compared with that in BDL G5 (p=0.059) (Fig. 6D ). week. 11 The present study also showed that the serum AST and ALT levels in the acute injury model (8-day bile duct-ligated rat model) were higher than those in the chronic injury model (22-day bile duct-ligated rat model). Zhu et al. 9 reported that rifaximin treatment did not lead to a statistically significant improvement in liver function after BDL. This was substantiated in the present study, as rifaximin treatment did not improve liver function in both acute and chronic injury models. These results indicate that rifaximin treatment cannot ameliorate the hepatocellular injury caused by BDL.
Kupffer cells (KCs) play a key role in modulating the inflammatory response observed in most animal models of liver injury. 12 LPS-induced activation of KCs in animal models leads to the secretion of a number of pro-inflammatory cytokines, such as TNF-α, interleukin 1 (IL-1), and IL-6. 13 Contrastingly, in response to LPS stimulation, freshly isolated human KCs secrete anti-inflammatory cytokine IL-10, which contributes to the downregulation of pro-inflammatory cytokines, and possibly, improved LPS tolerance of KCs. 14 Moreover, a previous study reported that the serum TNF-α level on the 14th day in the BDL group was not highly elevated compared with that in the controls, although it was highly elevated on the 7th day after BDL. 15 In the present study, the serum TNF-α level was elevated in the acute injury model than in the sham group after BDL. However, it was not significantly elevated in the chronic injury model when compared with that in the sham group after BDL. If the LPS levels were decreased by rifaximin treatment, the serum TNF-α level is expected to decrease.
However, such an effect was not observed after rifaximin treatment in the present study. There was a limitation in confirming the effects of rifaximin on anti-inflammation. Thus, further studies are necessary to detect other inflammatory cytokine pathways that is influenced by rifaximin treatment.
A previous report has shown that HSCs, and not KCs, are the primary targets driving fibrogenesis in response to TLR4 ligands. The same report also implicated TLR4 expressed on HSCs as the key driver of liver fibrosis owing to the stimulatory effects of TLR4 activation on the transforming growth factor-beta pathway. 16 Seki et al. 16 19 Therefore, studies for long-term treatment 246 신승각 등. 간섬유화와 리팍시민
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After all, our results showed that liver fibrosis in bile duct-ligated rat models was not only predominantly LPS-induced.
Therefore, rifaximin treatment, which mainly eradicates intestinal bacteria, may not completely prevent the development of liver fibrosis on its own.
Our study has several limitations to consider. First, the levels of intestinal microflora were not measured before and after the rifaximin treatment. Second, LPS levels were not measured, because the rifaximin treatment did not significantly affect the TNF-α level and fibrosis content. Third, other liver fibrosis models using hepatic toxins, such as carbon tetrachloride, thioacetamide, and diethylnitrosamine,
were not performed in our study. To elucidate more precise effects and mechanisms of rifaximin, further studies using various models of liver fibrosis will be necessary.
In conclusion, the short-and long-term effects of rifaximin treatment were unsatisfactory with respect to the inhibition of inflammation and fibrosis in bile duct-ligated rat models.
Although rifaximin only marginally inhibited liver fibrosis, the main mechanism behind liver fibrosis formation in bile duct-ligated rat models might not be LPS-dependent. If a spe- 
